Splash Image
About Us

Board of Directors

Commitment and Talent Taking Targeted Therapeutics to Market

Here at Northern Biologics, we combine world-renowned expertise in antibody generation and disease biology to create superior therapeutic antibodies.

Our strength is in our team, including the investors and leaders who make up our Board of Directors:

Brad Bolzon, PhD, Chair

Brad Bolzon, PhD

Chair

Brad Bolzon is a Managing Director with Versant Ventures. Brad brings more than thirteen years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups.

Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.

Jerel Davis, PhD

Jerel Davis, PhD

Jerel Davis is a Partner with Versant Ventures. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics, Laguna Pharmaceuticals and several of the Inception Sciences discovery start-ups. He has also led Versant’s execution of build-to-buy structured acquisitions with Celgene, Roche, and Bayer. Over the last few years, Jerel has focused on establishing Versant’s presence in Canada, including the launch of new companies in Vancouver, Toronto, and Montreal. Prior to joining Versant, Jerel was Associate Principal at McKinsey & Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical devices, and molecular diagnostics. He has worked in a number of healthcare markets globally including the US, Europe, China, Russia, and India. Jerel was a postdoctoral researcher at Stanford University until 2005 and in research at Amgen from 1999-2000.

Mary Haak-Frendscho, PhD

Mary Haak-Frendscho, PhD

Mary Haak-Frendscho serves as Chairman of the Board of Compugen, Inc., a subsidiary of Compugen, Ltd., devoted to translating in silico predicted targets into immuno-oncology therapeutics. Previously, she was CEO and member of the Board at Igenica Biotherapeutics, Inc. Prior to that, Dr. Haak-Frendscho was founding President, CSO and Board member of Takeda San Francisco, establishing and overseeing Takeda’s Center of Excellence for Biologics. Earlier in her career Dr. Haak-Frendscho held positions of increasing responsibility at XOMA, Abgenix (now Amgen), and Genentech, where she secured collaborative relationships with external corporate partners and led therapeutic antibody programs. At Genentech, she played a key role in the development of omalizumab (Xolair®).

Dr. Haak-Frendscho has authored over 70 scientific articles and has over 30 issued plus pending patents. An immunologist by training, Dr. Haak-Frendscho obtained her BS from the University of Michigan, MLA from Washington University in St. Louis, MS from SUNY-Stony Brook, CSEP from Columbia University Graduate School of Business and PhD from the University of Wisconsin, where she has an adjunct appointment in the Department of Pathobiological Sciences.

Stefan Larson, PhD

Stefan Larson, PhD

Stefan Larson is an Entrepreneur-in-Residence with Versant Ventures, and co-founded Northern Biologics in his role as President of Blueline Bioscience, a Toronto-based biotechnology incubator.

Prior to joining Versant, Stefan was the co-founding CEO of Tornado Medical Systems, a revenue stage scientific and medical instruments company with product lines in high performance Raman spectroscopy and optical coherence tomography. He began his professional career as a management consultant with McKinsey & Company, serving clients in the healthcare and technology sectors as an Associate Principal in the firm.

Stefan received his PhD in Biophysics from Stanford University, where he studied as a James H. Clark Graduate Fellow. He received his MSc in Molecular and Medical Genetics from the University of Toronto.

Ben Neel, MD, PhD

Ben Neel, MD, PhD

Ben Neel is the Director of the Laura and Isaac Perlmutter Cancer Center (LIPCC) and Professor of Medicine at NYU-Langone Medical School. Ben’s research focuses on cellular signal transduction, with a particular interest in the biology and regulation of protein-tyrosine kinases and phosphatases, the role of RAS/ERK pathway mutations in developmental disease and malignancy, and the functional genomics of breast and ovarian cancer.

Prior to LIPCC, Ben was the Director of Research at Princess Margaret Cancer Centre (PMCC), and Professor of Medical Biophysics and Tier 1 Canada Research Chair at the University of Toronto. Prior to PMCC, he was the William B. Castle Chair of Medicine at Harvard Medical School. Ben holds a PhD in Viral Oncology from Rockefeller University, and an MD from Cornell University.

Joan Seoane, PhD

Joan Seoane, PhD

Joan Seoane is currently the director of the Translational Research Program of the Vall d´Hebron Institute of Oncology (VHIO) integrated in the Vall d’Hebron University Hospital, head of the Gene Expression and Cancer Laboratory, and member of the Executive Board of VHIO. He is also an ICREA Research Professor and associate professor of the Autonomous University of Barcelona. He previously worked at the Memorial Sloan-Kettering Cancer as a Research Fellow and Research Associate. At VHIO, he has generated a multidisciplinary group focused on translational research in brain tumors. Joan’s group has identified several therapeutic targets against cancer, his publications have generated more than 4000 citations and has collaborated with several pharmaceutical companies (Eli Lilly, Novartis, MSD) to develop anti-cancer agents.